133 related articles for article (PubMed ID: 18421253)
1. Progress towards the use of HIV protease inhibitors in cancer therapy.
Bernhard EJ; Brunner TB
Cancer Biol Ther; 2008 May; 7(5):636-7. PubMed ID: 18421253
[TBL] [Abstract][Full Text] [Related]
2. Validation and toxicity of PI3K/Akt pathway inhibition by HIV protease inhibitors in humans.
Plastaras JP; Vapiwala N; Ahmed MS; Gudonis D; Cerniglia GJ; Feldman MD; Frank I; Gupta AK
Cancer Biol Ther; 2008 May; 7(5):628-35. PubMed ID: 18285707
[TBL] [Abstract][Full Text] [Related]
3. Nelfinavir, a new anti-cancer drug with pleiotropic effects and many paths to autophagy.
Gills JJ; Lopiccolo J; Dennis PA
Autophagy; 2008 Jan; 4(1):107-9. PubMed ID: 18000394
[TBL] [Abstract][Full Text] [Related]
4. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo.
Gupta AK; Cerniglia GJ; Mick R; McKenna WG; Muschel RJ
Cancer Res; 2005 Sep; 65(18):8256-65. PubMed ID: 16166302
[TBL] [Abstract][Full Text] [Related]
5. Targeting the AKT pathway: Repositioning HIV protease inhibitors as radiosensitizers.
Goda JS; Pachpor T; Basu T; Chopra S; Gota V
Indian J Med Res; 2016 Feb; 143(2):145-59. PubMed ID: 27121513
[TBL] [Abstract][Full Text] [Related]
6. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo.
Gills JJ; Lopiccolo J; Tsurutani J; Shoemaker RH; Best CJ; Abu-Asab MS; Borojerdi J; Warfel NA; Gardner ER; Danish M; Hollander MC; Kawabata S; Tsokos M; Figg WD; Steeg PS; Dennis PA
Clin Cancer Res; 2007 Sep; 13(17):5183-94. PubMed ID: 17785575
[TBL] [Abstract][Full Text] [Related]
7. Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention.
Gantt S; Casper C; Ambinder RF
Curr Opin Oncol; 2013 Sep; 25(5):495-502. PubMed ID: 23872785
[TBL] [Abstract][Full Text] [Related]
8. HIV protease inhibitors enhance the efficacy of irradiation.
Cuneo KC; Tu T; Geng L; Fu A; Hallahan DE; Willey CD
Cancer Res; 2007 May; 67(10):4886-93. PubMed ID: 17510418
[TBL] [Abstract][Full Text] [Related]
9. Nelfinavir: an update on its use in HIV infection.
Bardsley-Elliot A; Plosker GL
Drugs; 2000 Mar; 59(3):581-620. PubMed ID: 10776836
[TBL] [Abstract][Full Text] [Related]
10. The HIV protease inhibitor nelfinavir downregulates Akt phosphorylation by inhibiting proteasomal activity and inducing the unfolded protein response.
Gupta AK; Li B; Cerniglia GJ; Ahmed MS; Hahn SM; Maity A
Neoplasia; 2007 Apr; 9(4):271-8. PubMed ID: 17460771
[TBL] [Abstract][Full Text] [Related]
11. HIV protease inhibitor nelfinavir inhibits growth of human melanoma cells by induction of cell cycle arrest.
Jiang W; Mikochik PJ; Ra JH; Lei H; Flaherty KT; Winkler JD; Spitz FR
Cancer Res; 2007 Feb; 67(3):1221-7. PubMed ID: 17283158
[TBL] [Abstract][Full Text] [Related]
12. Postreceptoral adipocyte insulin resistance induced by nelfinavir is caused by insensitivity of PKB/Akt to phosphatidylinositol-3,4,5-trisphosphate.
Kachko I; Maissel A; Mazor L; Ben-Romano R; Watson RT; Hou JC; Pessin JE; Bashan N; Rudich A
Endocrinology; 2009 Jun; 150(6):2618-26. PubMed ID: 19179444
[TBL] [Abstract][Full Text] [Related]
13. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
14. Phosphoinositide-3-kinase inhibition enhances radiosensitization of cervical cancer in vivo.
Liu Y; Cui B; Qiao Y; Zhang Y; Tian Y; Jiang J; Ma D; Kong B
Int J Gynecol Cancer; 2011 Jan; 21(1):100-5. PubMed ID: 21330835
[TBL] [Abstract][Full Text] [Related]
15. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
[TBL] [Abstract][Full Text] [Related]
16. Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation.
Toulany M; Rodemann HP
Semin Cancer Biol; 2015 Dec; 35():180-90. PubMed ID: 26192967
[TBL] [Abstract][Full Text] [Related]
17. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
Kraus M; Müller-Ide H; Rückrich T; Bader J; Overkleeft H; Driessen C
Leuk Res; 2014 Mar; 38(3):383-92. PubMed ID: 24418752
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy.
Chen YL; Law PY; Loh HH
Curr Med Chem Anticancer Agents; 2005 Nov; 5(6):575-89. PubMed ID: 16305480
[TBL] [Abstract][Full Text] [Related]
19. Targeting PI3K/Akt/mTOR signaling pathway in the treatment of prostate cancer radioresistance.
Chang L; Graham PH; Ni J; Hao J; Bucci J; Cozzi PJ; Li Y
Crit Rev Oncol Hematol; 2015 Dec; 96(3):507-17. PubMed ID: 26253360
[TBL] [Abstract][Full Text] [Related]
20. Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations.
Dan S; Okamura M; Seki M; Yamazaki K; Sugita H; Okui M; Mukai Y; Nishimura H; Asaka R; Nomura K; Ishikawa Y; Yamori T
Cancer Res; 2010 Jun; 70(12):4982-94. PubMed ID: 20530683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
